$SPARK THERAPEUTICS INC(ONCE)$ is absolutely a competitor for $uniQure(QURE)$. It also uses AAV and has a pipeline that is certainly not superior to UniQure's. In my opinion, there is no reason UniQure should not have a market cap of around $1B at this time. The launch of Glybera and the start of the hemophilia clinical trial should help. However, we are trading at a third of Spark and that doesn't make sense.